Shenzhuo formulation ameliorates diabetic nephropathy by regulating cytochrome P450-mediated arachidonic acid metabolism

Figure 1 Shenzhuo formulation intervention improves renal injury in diabetic nephropathy mice. A diabetic nephropathy (DN) mouse model group (Model) was established and Shenzhuo formulation (SZF) intervention was given. A and B: SZF intervention significantly reduced blood glucose (A) and increased body weight (B) in DN mice; C-E: SZF intervention improves renal function in DN mice and reduces levels of 24-hour urinary total protein (C), creatinine (D), and BUN (E); F-G: SZF intervention improves the renal histopathological injury in DN mice; Hematoxylin and eosin staining results showing that SZF improves renal histopathological morphology; H and I: Masson staining results showing that SZF improves renal histopathological morphology and that SZF could reduce renal tissue fibrosis; J and K: PAS staining results showing that SZF could reduce renal tissue glycogen deposition. Data are presented as the mean ± SD. n = 10 per group. ^bP < 0.01 vs control group; ^cP < 0.05; ^dP < 0.01 vs Model; FBG: Fasting blood glucose; UTP: Urinary total protein; Cr: Creatinine; BUN: Blood urea nitrogen; DN: Diabetic nephropathy; HE: Hematoxylin and eosin; PAS: Periodic acid-Schiff; AOD: Average optical density; SZFH: Shenzhuo formulation high dose group; SZFL: Shenzhuo formulation low dose group; Control: Control group; PC: Positive control group; Model: Model group.